Introduction: This study aimed to address the underlying reasons for and clinical significance of the discordant EGFR mutation (EGFRm) status between tumor tissue (TT) and circulating tumor DNA (ctDNA).
Introduction
EGFR tyrosine kinase inhibitors (TKIs) have remarkably changed the treatment of patients with advanced NSCLC with sensitizing EGFR mutation (EGFRm) over the past decades. [1] [2] [3] [4] [5] The detection of EGFRm in tumor tissue (TT) specimens is still recognized as the accepted standard for determining EGFR TKI therapy. However, biopsy specimens provide only a snapshot of the whole tumor because of tumor heterogeneity, and they are difficult to obtained in almost one-third of cases. 6, 7 Seeking alternative specimens for genetic analysis is critical for clinical practice.
Circulating tumor DNA (ctDNA) has become a research hotspot because of its ability to overcome tumor heterogeneity and because of the ease of obtaining it noninvasively and dynamically. [8] [9] [10] Multiple previous studies, including our own, have shown a 60% to 80% concordance of EGFRm status between TT and matched blood specimens. 8, [10] [11] [12] The discordance of EGFRm status is due mainly to TT-positive/ctDNA-negative EGFRm status and less to TT-negative/ctDNA-positive EGFRm status. Low concentration of ctDNA and its constant elimination, as well as the relatively low sensitivity of the amplification refractory mutation system (ARMS), may contribute to TT-positive/ctDNA-negative EGFRm status. However, even the application of highly sensitive methods such as droplet digital PCR (ddPCR) and next-generation sequencing (NGS) for blood testing still resulted in a substantial proportion of patients showing TT-positive/ctDNA-negative EGFRm status, 9 implying other unknown mechanisms contributing to this clinical scenario.
Compared with TT-positive/ctDNA-negative EGFRm status, the presence of TT-negative/ctDNA-positive EGFRm status has met with some skepticism. Some investigators have speculated that intratumoral heterogeneity and sampling bias due to small biopsy specimens might contribute to the real existence of TT-negative/ ctDNA-positive EGFRm status. 12 Others consider TT-negative/ctDNA-positive EGFRm status a falsepositive amplification owing to signal drift. 13 However, some studies have demonstrated that patients with TT-negative/ctDNA-positive EGFRm status might benefit from EGFR TKI therapy, underlining the importance of identifying the accuracy of TT-negative/ctDNA-positive EGFRm status. 10, 14 The present study was aimed at investigating the reasons for the discordance of EGFRm status between TT and matched ctDNA samples in advanced NSCLC, and also optimizing the genotyping strategies for EGFRm detection in patients with advanced NSCLC.
Materials and Methods

Patient Population
This study included 5973 patients from Peking University Cancer Hospital and the Cancer Hospital of Chinese Academy of Medical Sciences who were evaluated for EGFRm in their ctDNA from March 1, 2005 , to March 31, 2015 , by using denaturing high-performance liquid chromatography (DHPLC) or ARMS assay. Of these 5973 patients, 2463 had matched TT samples. Patients who met the following criteria were further analyzed: (1) had EGFRm-positive status in TT samples and/or ctDNA determined by ARMS assay and (2) received EGFR TKI therapy. According to EGFRm status in their TT and ctDNA, patients were categorized into three groups: group A, positive EGFRm status in both TT and blood (TT-positive/ctDNA-positive status); group B, positive EGFRm status in blood only (TT-negative/ ctDNA-positive status); and group C, positive EGFRm status in tissue only (TT-positive/ctDNA-negative status). The TT specimens of patients in group B were reevaluated by ddPCR and NGS. The ctDNA of patients in group C was reevaluated by ddPCR.
The study was reviewed and approved by the institutional ethics committee at Peking University Cancer Hospital and the Cancer Hospital of the Chinese Academy of Medical Sciences. All patients had provided written informed consent before specimens were collected.
Specimen Collection and Processing
From all patients, 4 mL of venous blood was collected into ethylenediaminetetraacetic acid anticoagulated tubes before therapy administration, and kept at 4 C. The plasma was the separated within 4 hours; partial plasma was used for EGFRm detection immediately. and the other separated plasma was stored at -80 C for spare use. Plasma ctDNA was extracted and purified using a QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany).
TT specimens were collected from primary and/or metastatic sites by biopsy or surgical resection. DNA extraction from tumor specimens was performed by using tje E.Z.N.A. Formalin-Fixed Paraffin-Embedded DNA kit (Omega Bio-Tek, Norcross, GA). For patients in group B, formalin-fixed paraffin-embedded surgical specimens were stained with hematoxylin and eosin. As much nontumor content as possible was removed under a microscope, and the specimens were microdissected into small regions individually, and subjected to DNA extraction.
EGFR Mutation Analysis by Different Technologies
DHPLC. About 20% of the samples in this study were initially detected by DHPLC and confirmed by ARMS assay later. We performed DHPLC by using the Transgenomic Wave Nucleic Acid Fragment Analysis System with a DNASep column (Transgenomic, Omaha, NE). The mobile phase comprised 0.05% acetonitrile in 0.1 M triethylammonium acetate (eluent A) and 25% acetonitrile in 0.1M triethylammonium acetate (eluent B). The PCR products of exon 21 were denatured at 95 C for 5 minutes and cooled to 35 C at a rate of 1 C per minute to allow formation of heterozygote DNA. The product of exon19 did not need to be denatured. The flow rate was 0.9 mL/min, and an ultraviolet detector was set at 260 nm. We identified the heterozygous profiles by visual inspection of the chromatograms on the basis of the appearance of additional, earlier eluting peaks. Corresponding homozygous profiles showed only one peak.
ARMS. EGFRm status was analyzed by using the Human EGFR Gene Mutation Fluorescence PCR Diagnostic Kit (Amoy Diagnostics, Xiamen, China), which has been approved by the China Food and Drug Administration for use in in vitro diagnosis, 15 and all experiments were done by following the manufacturer's protocols. Briefly, 10 ng of genomic DNA extracted from TT or 5 mL of genomic DNA extracted from plasma was added to 45 mL of PCR master mix containing PCR buffer, DNA polymerase, fluorescent Taqman probes, and PCR primers. After 47 amplification cycles, the fluorescent signal was collected from 6-carboxy fluorescein (FAM) and hexachloro fluorescein channels. Genotypes were determined according to threshold count and/or change in count value, as indicated in the manufacturer's instruction. The data were analyzed with MxPro v4.10 software (Agilent Technologies, Waldbronn, Germany). This assay can cover the most common 29 types of EGFRm in lung cancers, including the following: 19 types of deletions in exon 19; three types of insertions in exon 20; and T790M, L858R, L861Q, G719X, and S768I point mutation.
ddPCR. We detected only EGFR 19del and L858R for each specimen by ddPCR; and the experiments were done at Amoy Diagnostics Co., Ltd. (Xiamen, China). The method of the ddPCR assays for EGFR 19del and L858R has been reported previously, and the established sensitivity was 0.04%. 16 Briefly, the ddPCR detection platform can create an emulsion of approximately 20,000 droplets with mutant and wild-type DNA, and the PCR reaction occurred in individual droplets. After the PCR reactions, each droplet produced a positive or negative fluorescence signal indicating whether EGFRm was present. For EGFR 19del assay, a 15-base pair (bp) peptide nucleic acid targeting the common 19del region, E746 to A750, was introduced to block the amplification of wild-type allele. The FAM-labeled probe targeting EGFR exon 19 amplicon of both wild-type and mutant alleles was used to reflect the existence of mutant with deletions within the peptide nucleic acid targeting region. A green fluorescent protein-labeled probe was designed to target EGFR exon 2 for total EGFR gene input control. The 19 common types of EGFR 19del from the ARMS assay kit were all covered by ddPCR assay. For EGFR L858R assay, FAM-labeled probe targeted the mutant region and green fluorescent protein-labeled probe targeted wild-type region were used to detect the mutant and wildtype allele, respectively. Human genomic DNA was included as a negative control and used to determine the cutoff for allele calling. We used QuantaSoft version 1.6.6.0320 software (Bio-Rad Lab, Hercules, CA) to analyze of the ddPCR data for allele calling. A single droplet occasionally showed up as a random event when nontemplate control reactions were tested. Therefore, samples that had at least two droplets in the positive area for the FAM signal were counted as positive for the mutation.
NGS. The DNA library was prepared by three-step PCR amplification. Briefly, the purified genomic DNA was linearly amplified in 25 mL of reaction mix containing 1Â NEBNext High-Fidelity PCR Master Mix (New England BioLabs, Ipswich, MA) and 150 nM primer A. Primer A was designed by inserting a sample barcode and a unique molecular identifier (UMI) between the 5 0 universal sequence and 3 0 EGFR target-specific sequence. The UMI can be used to label each EGFR molecular to make each cell population identifiable and remove PCR duplicates. The reaction was performed at 98 C for 30 seconds, 98 C for 10 seconds, 55 C for 5 minutes, and 72 C for 10 minutes, with holding at 4 C to create semiamplicons. Subsequently, single-stranded amplicons were amplified for just one cycle to obtain full amplicons by adding 5ml reaction mix containing 1Â NEBNext High-Fidelity PCR Master Mix and 150nM primer B. The reaction was immediately performed at 98 C for 30 seconds, 98 C for 10 seconds, 55 C for 5 minutes, and 72 C for 10 minutes. To avoid UMI resampling in the subsequent exponential PCR amplification and loss of PCR product, the full amplicons were purified twice with AMPure XP beads to remove the free primer A, primer B, and primer dimmers. Finally, the purified amplicons were amplified in 25 mL of reaction mix containing 1Â NEBNext High-Fidelity PCR Master Mix, 600 nM index primer, and 600 nM universal primer. The reaction was performed under the following conditions: 98 C for 30 seconds; 30 cycles of 98 C for 10 seconds, 65 C for 30 seconds, and 72 C for 30 seconds; 72 C for 5 minutes, and holding at 4 C. The final amplified product was purified with a QIAquick PCR purification kit (Qiagen) and eluted with 20 mL of nuclease-free water. The purified DNA was resolved on a 2% agarose gel, and the approximately 300-bp band was excised and purified. The purified DNA can serve as the library for sequencing on HiSeq X Ten sequencers (Illumina, San Diego, CA) as paired-end 150-bp reads. The primers used for NGS assay are described in Supplementary  Table 1 .
To evaluate the sensitivity of NGS assay for EGFR 19del and L858R mutations, DNA from PC-9 cells (harboring EGFR 19del mutation) and NCI-H1975 cells (harboring EGFR L858R mutation) were serially diluted with H9 cell DNA (with wild-type EGFR) to achieve decreasing radios (1:10 to 1:10,000) of 19del and L858R mutant allele versus the wild-type allele.
Statistical Analysis
Statistical analysis was performed with SPSS software, version 20.0 (IBM Corp., Armonk, NY). Frequency tabulation and summary statistics were provided to characterize the data distribution. The c 2 test was used to compare the objective response rate (ORR) among the three groups of patients receiving EGFR TKIs. The median progression-free survival (PFS) and overall survival (OS) of the three groups were calculated by KaplanMeier estimation and compared by standard log-rank test. A p value less than 0.05 was considered statistically significant.
Results
EGFRm Status at Baseline and Clinical Characteristics
Of 5973 patients who had been evaluated for EGFRm in ctDNA at baseline, 2463 had matched tissues samples and 1017 had EGFRm in their TT and/or ctDNA according to ARMS assay, including in both TT and ctDNA (n ¼ 644), in TT only (n ¼ 345), or in ctDNA only (n ¼ 28). Overall, the rates of detection of EGFRm in TT and ctDNA were 40.1% and 27.3%, with a concordance of 84.9%. The sensitivity and specificity of using ctDNA for EGFRm detection were 65.1% and 98.1%, respectively, compared with when TT was used. A total of 472 of 1017 patients received EGFR TKI therapy. Of these patients, 264 belonged to group A (TT-positive/ctDNApositive), 28 to group B (TT-negative/ctDNA-positive), and 180 to group C (TT-positive/ctDNA-negative). The schema for patient screening is shown in Figure 1 , and the detailed clinical characteristics of the three groups are listed in Table 1 .
Comprehensive Analysis of EGFRm Status in TT of Group B (TT-Negative/ctDNA-Positive) Patients
We first used ddPCR to confirm EGFRm status in the ctDNA of 28 patients in group B (16 cases of 19del and 12 cases of L858R), which showed that the detection results were concordant between ddPCR and ARMS assay. Subsequently, further investigations were carried out to check EGFRm status in 28 matched TT samples (Fig. 2) . With initial ddPCR, the EGFRm status of 10 patients (10 of 28) became positive in primary biopsy tissue specimens and that of two patients was found to be negative in primary tumor specimens but positive in liver metastasis specimens.
Of the rest of the 16 patients, 10 were found to harbor EGFRm in biopsy or surgical tissue specimens by NGS. For the 10 patients with positive EGFRm status by NGS (including six cases with 19del and four with L858R) (Fig. 3A-C) , the median mutation allelic frequency (MAF) was 1.13% (from 0.32% to 4.87%) determined by UMI counts. The remaining five patients were further found to carry EGFRm in microdissected surgical specimens by ddPCR. One patient failed to undergo NGS assay for lack of enough TT specimen.
To figure out the possible reason for TT-negative/ ctDNA-positive EGFRm status, genetic heterogeneity analysis was performed in the aforementioned five surgical specimens from patients who had undergone surgical resection of the primary tumor in group B. A median of 16 tumor foci (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) in each specimen were sliced, and a total of 78 foci were fractionated ( Supplementary Fig. 1A ). Only one of 78 foci had EGFRm detected by ARMS assay. However, 10 tumor foci from five tumor specimens were positive with a relatively low MAF ranging from 0.1% to 1.25% (median, 0.24%) by ddPCR ( Supplementary Fig. 1B ). In total, five patients demonstrated EGFRm intratumoral heterogeneity, with four EGFR 19del and one EGFR L858R mutation. The results demonstrated that tumor spatial heterogeneity contributed to TT-negative/ctDNA-positive EGFRm status ( Table 2) . Note: EGFR TKIs include erlotinib, gefitinib, and others such as icotinib. Tumor Tissue-Positive refers to EGFR mutation-positive in tumor tissue specimens, Tumor Tissue-Negative refers to EGFR mutation-negative in tumor tissue specimens, ctDNA-Positive refers to EGFR mutation-positive in blood specimens, and ctDNA-Negative refers to EGFR mutation-negative in blood specimens. ARMS, amplification refractory mutation system; TKI, tyrosine kinase inhibitor; ECOG PS, Eastern Cooperative Oncology Group performance status; AD, adenocarcinoma; Non-AD, nonadenocarcinoma; EGFRm, EGFR mutation.
Comprehensive Analysis of Discordance in Group C (TT-Positive/ctDNA-Negative EGFRm Status)
In group C, 180 patients showed EGFRm in tissues but not in ctDNA as detected by ARMS assay at baseline. When all ctDNA specimens were reevaluated with ddPCR, the EGFRm status of 64 ctDNA specimens changed from negative to positive.
To identify the potential effect of tumor burden on the ability to detect EGFRm in ctDNA, we compared tumor burden between patients with or without EGFRm in ctDNA, as detected by ddPCR. The results showed that EGFRm positivity in ctDNA conferred a higher likelihood of heavy tumor burden (!2 versus <2 organ metastatic sites) than EGFRm negativity in ctDNA (p ¼ 0.011).
Despite the use of highly sensitive ddPCR, there were still 116 patients whose ctDNA specimens remained EGFRm negative. Thus, the false-negative rate was 26%. Actually, in this retrospective study, the blood specimens were collected at different time points daily before initiation of the EGFR TKI. To identify the potential influence of blood collection time points on EGFRm status, the blood specimens from 21 patients were collected at three time points within 1 day (at 8 AM, 11 AM, and 2 PM) for EGFRm analysis by ddPCR (all patients had enrolled to trial NCT02282267 and been identified as harboring EGFRm in ctDNA on different days). In a total of 63 blood specimens, the MAF of EGFRm was 0.06 (0-0.35), and among them, 14 specimens had a MAF of EGFRm less than a 0.01. Moreover, there were still seven time point blood specimens lacking EGFRm even according to ddPCR. In total, the MAF of EGFRm changed dynamically across different time points within 1 day (Supplementary Fig. 2 ).
Correlation between EGFRm Status and Clinical Outcomes of EGFR TKI Treatment
To emphasize the clinical significance of different EGFRm status, the efficacy and survival outcomes of EGFR TKIs were evaluated. There was no significant Fig. 4C and D) . Neither TT-positive nor ctDNA-positive EGFRm status could identify all EGFR-mutant cases, although the patients in these two groups demonstrated satisfactory clinical outcomes after EGFR TKI therapy.
Comparison of Patterns for EGFRm Detection Based on the Test Sequence of TT and ctDNA
Because EGFRm detection relying only on TT or ctDNA exclusively could not accurately reflect EGFRm status, combined utilization of TT and ctDNA was needed. Detecting EGFRm initially in TT and then in ctDNA if the results of testing tissue samples are negative or if sufficient tissue specimens are not available (TT/ctDNA pattern) is currently a common clinical practice. Here, we assessed the potential viability of a Patient underwent NGS analyses. EGFRm, EGFR mutation; TKI, tyrosine kinase inhibitor; ARMS, Amplification refractory mutation system; ddPCR, droplet digital polymerase chain reaction; NGS, next-generation sequencing; PFS, progression-free survival; OS, overall survival; PR, partial response; PD: progressive disease; ctDNA, circulating tumor DNA; WT, wild type; NA, not available.
different procedure for EGFRm detection to determine EGFR TKI therapy by testing for EGFRm in ctDNA as primary screening and then using tissue as a supplementary test if the ctDNA failed to demonstrate positive EGFRm status (ctDNA/TT pattern). To compare these two patterns under the clinical demand for maximum identification of patients with real EGFR mutation, the number of ARMS assays and tissue specimens used were analyzed as parameters. The detailed mathematical analysis process is shown in the Supplementary Data.
Consequently, the ctDNA/TT pattern might save about 30% of TT specimens, although it might utilize an additional 6% for ARMS assays compared with the TT/ctDNA pattern ( Supplementary Fig. 3 ).
Discussion
In this large retrospective study, we explored the underlying reasons for discordance of EGFRm status between TT and ctDNA and stressed its clinical significance. Three major findings were as follows: (1) the intratumoral heterogeneity and relatively low sensitivity of ARMS assay contributed to the false-negative EGFRm status result in biopsy specimens or ctDNA; (2) patients with EGFRm TT-negative/ctDNA-positive status could benefit from EGFR TKIs, although they represented a subtype of EGFR-mutated NSCLC with a low MAF and significant tissue heterogeneity; and (3) by ARMS assay, testing for EGFRm status only in tissues or only in ctDNA could not detect all patients with EGFRm-positive status. A blood test for EGFRm as primary screening followed by TT testing in the case of a negative result (ctDNA/TT pattern) may be a preferable approach to determine EGFR TKIs therapy because of the similar detection efficiency and expansion of the group of patients without tissues compared with the TT/ctDNA pattern.
Previous studies involving EGFRm in matched tissues and ctDNA reported that patients with TT-negative/ ctDNA-positive EGFRm status ranged from 1% to 10%. [8] [9] [10] 17, 18 False-negative detection of T790M mutation in tissues was also observed in recent clinical trials for the third-generation EGFR TKIs AZD9291 and CO1686. 19, 20 Indeed, the presence of TT-negative/ ctDNA-positive EGFRm status had been meeting with some skepticism. However, almost all studies involving EGFRm detection in matched ctDNA and TT samples reported the subgroup of TT-negative/ctDNA-positive EGFRm status. 8, 10, 12, 18, 21, 22 We tended to believe that this was a false-negative result in TT samples. First, the group with TT-negative/ctDNA-positive EGFRm status also included relatively high percentages of women (57.1%), never-smokers or light smokers (67.9%), and patients with pulmonary adenocarcinomas (89.3%). Previous studies showed that these populations had a high incidence of EGFR-sensitive mutations. 23, 24 Second, we confirmed the mutation status of ctDNA by different methods: ARMS and ddPCR. Although only one of 78 foci showed positive EGFRm status by ARMS assay, 10 foci distributed in five specimens demonstrated positive EGFRm status by ddPCR, meaning that the detection rate was increased along with the improvement in method sensitivity. This result also illustrated that tumor heterogeneity contributed to "missing" EGFRm in TT. 25 Third, although the ORR and median PFS of the EGFRm TT-negative/ctDNA-positive group were inferior to those of EGFRm TT-positive/ctDNA-positive and EGFRm TT-positive/ctDNA-negative groups, the PFS of the EGFRm TT-negative/ctDNA-positive group (6.5 months) was superior to that of the group with TT-negative/ ctDNA-negative EGFRm status (about 1 month in a previous study 26 ). This result also suggested the reality of EGFRm in the group with TT-negative/ctDNA-positive EGFRm status. It should be noted that 75% of patients (21 of 28) in the group with TT-negative/ctDNA-positive EGFRm status were tested initially by ARMS assay of small biopsy specimens. This demonstrated that it was difficult for single biopsy specimens to reflect the genetic characteristics of the whole tumor in heterogeneous lung cancers. However, we could not rule out that some of these results might be false-positive in ctDNA, because these patients had a relatively higher smoking status than those in groups A and C (p ¼ 0.048) and because of the fact that these patients had a shorter PFS and OS, which could lead to the potential risk of inappropriate selection of patients for treatment with EGFR TKIs. This question can be resolved by a comprehensive analysis of the clinicopathological characteristics of patients that confirms the mutation status of TT with a more sensitive method.
We and other investigators had previously reported that intratumoral heterogeneity might influence the clinical outcomes of EGFR TKIs. In this study, our results demonstrated that TT-negative/ctDNA-positive EGFRm status was due to the low MAF of EGFRm in heterogeneous tumors and that this subgroup of patients presented numerically inferior PFS in response to EGFR TKIs, suggesting that further exploration of the influence of quantitative detection of EGFRm on clinical outcomes is merited. Despite this, the PFS of patients with TT-negative/ctDNA-positive EGFRm status who received EGFR TKIs was superior to that of patients who received chemotherapy, [27] [28] [29] highlighting the clinical importance of identifying those patients with TT-negative/ctDNApositive EGFRm status for EGFR TKI therapy. Although patients with TT-negative/ctDNA-positive EGFRm status represented only a limited number of clinical cases, they might lose the chance to receive EGFR TKI treatment if the clinical decision is based only on results of detection of EGFRm status on the basis of biopsy tissue specimens.
In this study, 26% of patients showed false-negative EGFRm in ctDNA even by ddPCR. The detection limit of ddPCR for gene mutation had been reported to range from 0.04% to 0.1%. 16, [30] [31] [32] A recent study showed that the sensitivity was about 90% with deep sequencing by NGS, which suggested that blood testing even by NGS could not find all true positives, and thus, that false-negative results could be caused by unknown mechanisms other than sensitivity of the assay method. We therefore speculated that false-negative results of testing for EGFRm status in ctDNA might be partially due to the release, distribution, and clearance of ctDNA. Our present data showed that false-negative EGFRm in ctDNA might occur at each time point within 1 day, implying that the abundance of EGFRm might change dynamically. These results provided some evidence that the photokinetics of ctDNA is one important factor influencing the efficiency of detection of EGFRm in blood.
In China, not all patients with metastatic lung cancer can provide sufficient TT for or afford NGS-based genetic analyses. The key driver gene aberrations such as EGFR mutation, KRAS mutation, ALK receptor tyrosine kinase gene (ALK) fusion, and ROS1 rearrangement identified as a single analytic is the most popular procedure. Thus, saving TT for more genetic analyses besides EGFRm testing and for future exploratory research is important. Actually, neither tissue nor ctDNA seems to identify all "real" EGFR-mutant cases, suggesting that a combination of tissue and ctDNA tests might have important clinical meaning. This study illustrated the feasibility of the ctDNA/TT approach for EGFRm detection, which could conserve more tissue specimens compared with the TT/ctDNA pattern. Recently, the ctDNA/TT approach for EGFR T790M detection after resistance to EGFR TKIs has been proposed, especially when it is difficult to perform a repeat biopsy. Actually, the ctDNA/TT sequence for initial EGFRm detection might also have important clinical significance. First, only about 70% of patients can provide sufficient tissue specimens for further genetic analysis after initial pathologic qualitative analysis. Second, the time gap from preparation for biopsy of TT for gene detection is significantly longer than that for preparation for a blood test for gene mutation analysis. These factors highlight the advantage of the ctDNA/TT sequence. Moreover, the process explored in our study for EGFRm detection by ARMS assay could be extended to other aberrant gene detection even in multigene analyses by other methods such as ddPCR and NGS. These results suggested that the ctDNA/TT sequence of molecular analyses might be a preferable approach. However, additional studies are needed to support this conclusion.
